Product image of Kesimpta (Ofatumumab) supplied by GNH India

Kesimpta

Active Ingredient:
Ofatumumab
Origin:
EU

Kesimpta (Ofatumumab)

Ofatumumab, the active ingredient in Kesimpta, is a monoclonal antibody presented as a solution for subcutaneous injection. It is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing‑remitting MS, and active secondary progressive MS in adult patients and is administered under medical supervision.

GNH India supplies Kesimpta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Kesimpta (ofatumumab) is a disease‑modifying therapy that targets B‑cell activity in multiple sclerosis.
  • Clinically isolated syndrome: reduces risk of progression to definitive multiple sclerosis.
  • Relapsing‑remitting multiple sclerosis: lowers annual relapse rate and slows disability accumulation.
  • Active secondary progressive multiple sclerosis: decreases relapse activity and may delay disability worsening.

How It Works

  • Ofatumumab binds selectively to the CD20 antigen on B‑lymphocytes, triggering B‑cell depletion through complement‑dependent cytotoxicity and antibody‑dependent cellular cytotoxicity. This reduction of circulating B cells modulates the immune response implicated in the pathogenesis of multiple sclerosis, thereby decreasing inflammatory activity within the central nervous system.

Side Effects

The most frequently reported adverse reactions and the less common but serious events are listed below.

Common Side Effects

  • Injection site reactions: redness, swelling, or pain at the injection site.
  • Upper respiratory tract infection: mild cold‑like symptoms.
  • Headache: transient mild to moderate headache.
  • Fatigue: general tiredness without specific cause.
  • Nausea: occasional mild nausea.
  • Mild infections: increased susceptibility to common infections.

Serious or Rare Side Effects

  • Severe infections: bacterial, viral, or fungal infections requiring medical attention.
  • Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection.
  • Anaphylaxis: severe allergic reaction with respiratory or cardiovascular compromise.
  • Hepatitis B reactivation: flare of chronic hepatitis B infection.
  • Neutropenia: low neutrophil count increasing infection risk.
  • Immune‑mediated disorders: autoimmune conditions such as thyroiditis.

Precautions & Warnings

  • When using Kesimpta, several safety considerations should be observed.
  • Infection monitoring: assess for signs of infection before and during therapy.
  • Hepatitis B screening: test patients for hepatitis B prior to initiation.
  • Vaccination status: update non‑live vaccines before starting treatment.
  • Hypersensitivity: discontinue if severe allergic reaction occurs.
  • Active severe infection: avoid initiating therapy in patients with ongoing serious infections.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Kesimpta may interact with other medicines or vaccines; relevant interactions are categorized by clinical significance.

Major Interactions (Avoid)

  • Live vaccines: contraindicated due to immunosuppression risk.
  • Concurrent B‑cell depleting agents: may cause excessive immunosuppression.
  • Immunosuppressive chemotherapy: increased infection risk.

Moderate Interactions (Monitor Closely)

  • Non‑live vaccines: may have reduced efficacy; monitor immune response.
  • Antifungal azoles (e.g., ketoconazole): may affect drug clearance; observe for adverse effects.

Frequently Asked Questions

Kesimpta is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive multiple sclerosis. It is used to reduce relapse frequency and slow disability progression in adult patients.

Ofatumumab is a monoclonal antibody that binds to the CD20 protein on B‑lymphocytes. This binding triggers complement‑dependent cytotoxicity and antibody‑dependent cellular cytotoxicity, leading to depletion of CD20‑positive B cells and modulation of the immune processes that drive multiple sclerosis activity.

The dosing regimen for Kesimpta is determined by the prescribing physician based on the patient’s clinical condition and regulatory guidelines. The prescriber decides the initial loading schedule and subsequent maintenance doses, which are administered by subcutaneous injection.

Safety data for Kesimpta during pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and it is generally recommended to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To order Kesimpta, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including cold‑chain handling) and any required import documentation.

Kesimpta belongs to the class of B‑cell depleting monoclonal antibodies, similar to ocrelizumab. Compared with some oral disease‑modifying drugs, it offers a targeted mechanism that may provide a different safety profile, particularly regarding infection risk. Choice of therapy depends on individual disease characteristics, tolerability, and physician assessment.

Kesimpta should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temperature excursions occur, follow the manufacturer’s guidance before use.

Kesimpta is supplied as a solution for subcutaneous injection. The injection is performed by a qualified healthcare professional, typically in the abdomen, thigh, or upper arm, following the dosing schedule prescribed by the treating physician.

Serious risks include severe infections such as bacterial, viral, or fungal diseases, progressive multifocal leukoencephalopathy (PML), anaphylactic reactions, hepatitis B reactivation, neutropenia, and other immune‑mediated disorders. Patients should be monitored closely for signs of infection or allergic response and report any concerning symptoms promptly.

Kesimpta should not be used in patients with active severe infections, known hypersensitivity to ofatumumab or any excipients, or in individuals receiving live vaccines. Caution is also advised for patients with chronic hepatitis B infection, as reactivation can occur.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ofatumumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT